Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2005

01-01-2005 | Report

SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1 β in vivo andin vitro

Authors: Feng-mei Wang, Hou-qi Liu, Shan-rong Liu, Shu-ping Tang, Ling Yang, Gen-sheng Feng

Published in: Breast Cancer Research and Treatment | Issue 1/2005

Login to get access
Metadata
Title
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1 β in vivo andin vitro
Authors
Feng-mei Wang
Hou-qi Liu
Shan-rong Liu
Shu-ping Tang
Ling Yang
Gen-sheng Feng
Publication date
01-01-2005
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-004-1002-z

Other articles of this Issue 1/2005

Breast Cancer Research and Treatment 1/2005 Go to the issue

Report

Reduced rates of cancer-related worries and mortality associated with guideline surveillance after breast cancer therapy

OriginalPaper

Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer

Report

High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma

Report

The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database

Report

The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life

OriginalPaper

Relationship of depression to patient satisfaction: findings from the barriers to breast cancer study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits